GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
Language English Country United States Media print-electronic
Document type Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
35902330
DOI
10.1016/j.tem.2022.06.005
PII: S1043-2760(22)00122-9
Knihovny.cz E-resources
- Keywords
- GLP-1 receptor agonist, antipsychotic, metabolic adverse effects, pro-cognitive, schizophrenia,
- MeSH
- Glucagon-Like Peptide-1 Receptor Agonists MeSH
- Antipsychotic Agents * adverse effects MeSH
- Diabetes Mellitus, Type 2 * drug therapy MeSH
- Glucagon-Like Peptide 1 therapeutic use MeSH
- Weight Gain MeSH
- Hypoglycemic Agents therapeutic use MeSH
- Humans MeSH
- Obesity chemically induced drug therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Glucagon-Like Peptide-1 Receptor Agonists MeSH
- Antipsychotic Agents * MeSH
- Glucagon-Like Peptide 1 MeSH
- Hypoglycemic Agents MeSH
Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs). Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically significant domain of serious mental disorders, cognitive impairment. Moreover, adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during treatment with APDs. Among pharmacological candidates reversing APD-induced metabolic adverse effects, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for both diabetes and recently for obesity treatment, stand out due to their favorable effects on peripheral metabolic parameters. Interestingly, GLP-1 RAs are also proposed to have pro-cognitive effects. Particularly in terms of dual therapeutic mechanisms potentially improving both central nervous system (CNS) deficits and metabolic burden, GLP-1 RAs open a new perspective and assume a clinically advantageous position.
References provided by Crossref.org
